Lung cancer remains the leading cause of cancer-related deaths in the United States, with an estimated 125,000 fatalities expected this year, surpassing deaths from colon, breast, or prostate cancers. Despite this, screening rates for lung cancer among those eligible remain notably low. Recent data indicate that only about 25% of patients who meet the criteria actually receive recommended annual low-dose computed tomography (CT) scans.

Dennis Schmidt, 75, a former smoker and healthcare professional from Indiana, exemplifies both the risks and benefits associated with lung cancer screening. Schmidt smoked menthol cigarettes for nearly four decades, quitting in 2007 with the aid of a prescription medication. Unaware until recently that screening was available for former smokers, he agreed to a lung cancer CT scan during a 2021 Medicare wellness visit. The scan detected adenocarcinoma—an early-stage lung cancer. Following robotic surgery to remove the tumor, ongoing surveillance identified and allowed treatment of a second early-stage cancer in 2025. Schmidt now continues targeted drug therapy and regular screenings while maintaining an active lifestyle.

National guidelines for lung cancer screening come primarily from the U.S. Preventive Services Task Force (USPSTF), which in 2013 initially recommended annual low-dose CT scans for adults aged 55 to 80 with a history of heavy smoking. These guidelines were updated in 2021 to lower the starting age to 50 and reduce the smoking history criterion to 20 pack-years, applying to current smokers or those who quit within the past 15 years. "Pack-years" quantify smoking exposure, calculated as the number of cigarette packs smoked daily multiplied by years smoked.

Although these guidelines aim to identify high-risk individuals, both physicians and patients often find determining eligibility challenging. “Smoking patterns vary over time,” said Dr. Teva Brender of the San Francisco VA Medical Centre. Additionally, stigma surrounding tobacco use may deter some from disclosing smoking histories, further complicating screening efforts.

Studies have demonstrated the effectiveness of screening in reducing lung cancer mortality. A 2011 clinical trial showed a 20% reduction in deaths from lung cancer with annual low-dose CT scans compared to chest X-rays. More recent European research reported up to a 39% mortality reduction after ten years of screening. Despite such evidence, many eligible individuals do not receive these potentially life-saving scans.

Screening rates are higher among adults over 65 compared to younger adults, yet even in this group only about one-third undergo regular scans, lagging behind other cancer screenings like colonoscopies and prostate tests. Experts caution that expanded screening could lead to false positives, additional testing, anxiety, and radiation exposure.

There is ongoing debate about the eligibility criteria. Organizations including the American Cancer Society and the National Comprehensive Cancer Network have relaxed screening guidelines by eliminating the 15-year quit-time requirement, arguing that risks remain elevated long after smoking cessation. They advocate broader screening access, while the USPSTF has yet to update its recommendations following these proposals.

Treatment options for lung cancer have improved substantially, with advances in minimally invasive surgery and targeted drug therapies contributing to better outcomes. Early detection through screening increases the likelihood of successful treatment and survival; approximately 80% of patients diagnosed at an early stage survive five years or more.

While screening can improve outcomes, experts emphasize that quitting smoking remains paramount in reducing lung cancer risk. Dr. Steven Woloshin of the Dartmouth Institute noted, “The risk is lower the longer you are away from cigarettes, but it doesn’t go to zero.” The combination of smoking cessation, timely screening, and effective treatment offers the best strategy to combat lung cancer mortality in the aging population.